In a prospective cohort study, we tested the hypothesis that children with sickle cell anemia (SCA) with normal transcranial Doppler ultrasound (TCD) velocities and without silent cerebral infarcts (SCIs) would have a lower incidence rate of new neurological events (strokes, seizures or transient ischemic attacks) compared to children with normal TCD measurements and SCIs, not receiving regular blood transfusions. Nonrandomized participants from the silent cerebral infarct transfusion (SIT) Trial who had screening magnetic resonance imaging (MRI) of the brain and normal TCD measurements were included. Follow-up ended at the time of first neurological event (stroke, seizure or transient ischemic attack), start of regular blood transfusion, or loss to follow-up, whichever came first. The primary endpoint was a new neurological event.
| I N TR ODU C TI ON
Strokes and other neurological complications in sickle cell anemia (SCA) are a major cause of morbidity in children living in high and low resource settings. 1 Strokes are still a major risk factor for death in children living in low resource settings, where primary and secondary stroke prevention strategies are not part of routine care. 2, 3 Completion of six clinical trials in children with SCA has clearly identified the group of children with the highest risk of initial and recurrent strokes. [4] [5] [6] [7] [8] A pooled analysis of stroke recurrence in children with initial overt strokes not receiving any treatment for secondary prevention showed that they have the highest rate of future strokes, 29 events per 100 patient-years. 9 Children with elevated transcranial Doppler ultrasound (TCD) velocities who do not receive regular long-term blood transfusions have the highest incidence of initial strokes, 10.7 per 100 patient-years. 10 No cohort of children with SCA has been identified with the lowest stroke incidence rate. Specifically, no multi-center prospective cohort study of children has determined whether children with a normal TCD measurement (time averaged mean maximum velocity of < 200 cm/second, nonimaging or <185 cm/second, imaging technique) and absence of silent cerebral infarcts (SCIs), have a low rate of strokes or other neurological events.
To address the absence of data estimating the stroke incidence rate in SCA children with normal TCD measurements and without SCIs, 
| M E TH ODS

| Study design
The SIT Trial was a multi-center clinical trial in which children with SCA and SCIs were randomized to either blood transfusion therapy or observation. 8 The trial was approved by Institutional Review Boards (IRB) at all 26 participating institutions and registered at www.clinicaltrials.gov (NCT00072761) and www.ISRCTN.org (ISRCTN52713285).
Parents provided written informed consent and participants provided assent in accordance with local IRB procedures. This planned ancillary study was approved by the SIT Trial Executive Committee and reviewed by the Data and Safety Monitoring Board. Twenty-three sites chose to participate in this prospective longitudinal study of all screened participants. As part of routine care, participants were followed from the time of the initial magnetic resonance imaging (MRI) of the brain until a site visit was performed to specifically collect designated data from the medical records. To ensure uniform collection of information, data were retrieved from the medical records after a visit 
| Primary outcome
The primary outcome was the incidence of new neurologic events defined as stroke, seizure or TIA. Seizure was included as a new neurological event because seizures may reflect new cerebral ischemia in children with SCA. [12] [13] [14] [15] Definitions of cerebrovascular events:
| Overt stroke
Neurological deficit consistent with a stroke and new ischemic or hemorrhagic lesion on MRI that could explain the deficit. Overt strokes were sub-categorized as ischemic or hemorrhagic.
| MRI-negative stroke
The SIT Trial neurology committee determined that an event was an MRI-negative stroke based on presentation consistent with stroke, neurological deficits lasting for > 24 hours, and negative brain MRI at the time of evaluation.
| Silent cerebral infarct (SCI)
The presence of SCI was determined by the neurology committee gist's examination. However, these participants were not deemed to have a stroke locally based on the hematologist's decision not to recommend regular blood transfusion therapy, a standard care intervention for secondary prevention of strokes in SCA, and were thus included in this analysis. 16 
| Transient ischemic attack (TIA)
Clinical picture consistent with stroke and neurological deficit for < 24 hours and negative brain MRI.
| New seizure
Focal or generalized seizure occurring in a child without a history of seizure at the time of study entry.
| Neurology examination
A pediatric neurologist completed the standardized neurological examination at each study site to determine eligibility for the SIT Trial using the pediatric stroke outcome measure (PSOM). The PSOM is a validated, reliable outcome measure 17 that consists of standard neurological examination items (mental status, cranial nerves, motor, sensory, cerebellar, and gait). At the conclusion of the PSOM, the clinician completes a summary of impressions that measures neurological function across five subscales: sensorimotor (right and left), language comprehension, language production and cognitive or behavioral deficit. The total PSOM is summed from the individual five sub-scales and ranges from 0 (no deficits) to a maximum score of 10. Head CT was not considered adequate to distinguish an ischemic stroke from a TIA.
| Study procedures
| Sample characteristics
The sampling frame for this study was the population of children that completed a screening brain MRI for the SIT Trial, had at least one TCD measurement, and were followed until they developed a neurological event or for at least a year after signing the informed consent. Table S1 ).
| R E SU LTS
| Demographics
In the SIT Trial, 1176 children consented for screening, 1063 com- 8, 19 and were determined locally as having SCI(s). However, further review by the SIT trial neurology committee indicated that two participants should be considered as meeting the definition of stroke, although neurological findings were subtle (n 5 2), both children had very mild hemiparesis and one had cognitive difficulties. The local site hematologists did not consider these participants as having a stroke, but rather having SCI, and elected not to offer regular blood transfusion therapy, as would be standard care for an overt stroke.
3.2 | Presence of silent cerebral infarct was associated with a higher incidence of future neurological events Table 2 , while further detail for those with seizures is given in Supporting Information Table S2 . The incidence rate of new events for those with and without SCIs at baseline, Table 1 , was 1.71 (4 events in 234.2 patient-years) and 0.47 (6 events in 1286.2 patient-years) per 100 patient-years, respectively (P 5 .065). The proportion of children that remained neurological event-free over time is shown in Figure 1, with a difference between the two groups (log rank test, P 5 .032). A Cox regression model, including a propensity score for SCI at baseline, Supporting Information Table S3 , found that absence of SCI at baseline was associated with a decreased risk of a new neurological event (hazard ratio 0.231, 95% CI 0.062-0.858; P 5 .029).
| Neurologists add value to detect subtle strokes in children believed to have silent cerebral infarcts
Due to the unique study design, we were able to compare the site hematologist's neurological assessment of normal examination (an entry neither was transfused and both had subsequent neurological events.
Despite the central committee's review, the site hematologists still considered these two individuals as having SCIs and not strokes, and elected not to put these children on regular blood transfusion therapy or hydroxyurea therapy.
For our results to mimic clinical practice, we utilized the hematologist's neurological examination and their classification of SCIs in our primary analysis. However, given the discordance between the pediatric hematologist's and neurologist's evaluation for stroke, we reanalyzed the data with the pediatric neurologist's and neurology committee's evaluation. Thus, of 68 children with SCI at baseline, two children were re-classified as having strokes and not a SCI. One of the children with a neurologist-identified overt stroke at baseline had a seizure and the other had an ischemic stroke during a pain crisis (Table 2) . With exclusion of these two children from the SCI group, 3.0% (2 of 66) and 1.7% (6 of 353) developed neurological events with and without pre-existing SCIs, P 5 .618 and the log rank test was P 5 .447.
The site neurologists, without the benefit of the MRI of the brain, also had challenges in identifying a child with a stroke, when compared to the neurology committee that had access to both site neurologist's examination and the MRI of the brain revealing the location of the cerebral infarct. The site neurologists graded 30% (20 of 67) of the neurological examinations as abnormal (PSOM >0). Site neurologists recorded significant concerns about two children with total PSOM >1.5; only one of the two children was confirmed as having a stroke.
The child with stroke had both a subtle hemiparesis and cognitive difficulties. The other child was not a native English speaker and the examination was challenging with concerns regarding language and cognition; however, there were no focal motor or sensory findings, and a SCI-like lesion was not present on imaging. There were moderate concerns about two children each with total PSOM 5 1. In the two children, the neurology committee confirmed one child had a stroke based on subtle right hemiparesis, and one child had significant cognitive difficulties, but not a confirmed stroke. Site neurologists graded the remaining 16 children as having very mild abnormalities on examination (PSOM 5 0.5 for cognitive or language concerns). The SIT Trial neurology committee did not adjudicate any of these 16 children as having a stroke.
| D ISC USSION
The goal of clinical trials for primary and secondary stroke prevention in children with SCA is to identify the subgroup of children at the highest risk for future neurological injury, and to determine whether an intervention (blood transfusion, hydroxyurea or both) prevents overt stroke or infarct recurrence. After completion of six clinical trials in children with SCA, children with strokes, SCIs, and abnormal TCD velocities have higher rates of neurological events when compared to children without strokes, SCIs and normal TCD velocities.
However, we have less evidence to identify those at low risk for future neurological events because children believed to be at low risk for neurological events have been excluded from these controlled trials. We have demonstrated in a prospective multi-center observational study the lower incidence rate of overt neurological events (stroke, TIA, seizure) in children with normal TCD measurements and without SCIs, when compared to children with normal TCD measurements and SCIs. However, even in children with SCA considered to have the lowest stroke risk, their stroke incidence rate is still at least 100-times higher at 0.47 per 100 patient-years than the stroke incidence rate in the general population of children without SCA, 0.003 per 100 patient-years. 20 The rate of all new neurological events for those children with SCIs and normal TCD measurements was similar to the rate in the group of children in the SIT Trial randomized cohort that did not receive treatment (observation group). In the observation arm of the SIT trial based on intention to treat analysis, the incidence rate of neurological events was 3.1 events per 100 patient-years (7 strokes, 2
TIAs, 0 seizures in 289 total patient-years) compared to the current analysis of 1.7 events per 100 patient-years (5 strokes, 3 TIAS, and 2 seizures) in children with SCIs and normal TCD values. We also compared our findings to previously published studies of children with SCA ( Figure 2 ) and show that even with normal TCD and MRI of the brain, children with SCA have a much higher rate of stroke than the general population of children.
In children with SCA, a neurological examination to define a stroke is often challenging even for an experienced pediatric neurologist. In a child with SCA, an accurate assessment of the neurological status to determine the presence of stroke, SCIs, or neither requires a complete patient-years and 29 per 100 patient-years, respectively.
9
As anticipated, this ancillary study had several strengths and limitations. Our prospective multi-center cohort included the largest number of children with SCA followed for an average of 3 years. Thus, our results are generalizable to children with SCA and normal TCD measurements with and without SCIs, the former group (normal TCD and no SCIs) never having been evaluated prospectively in a multi-center study.
To reflect clinical practice, we utilized the hematologist's neurological examination and their classification of SCIs. We excluded the research evaluation of the site neurologists that identified an abnormal neurological finding in 30% of the participants and the neurology committee's adjudication, neither of which would be considered standard care. The site neurologist did not have the benefit of reviewing the MRI when examining the patient, while the neurology committee had a panel of pediatric stroke experts to discuss the nuances of the case.
However, when we used the site neurologist's examination and neurology committee adjudication and reclassified two children with subtle neurological findings as having strokes, the incidence of neurological events was still nearly double that in the group with pre-existing SCIs and normal TCD velocities when compared to the group with no SCI and normal TCD velocities, but no longer statistically significant.
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